CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial
On March 4, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced a collaboration agreement with Abbott to support the company's pivotal TECarfarin...
474 Views
CVKD: Recent Financings Raise 9.8 Million
On November 7, 2024, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the third quarter of 2024 and provided a business...
299 Views
CVKD: New Blood Thinner Ready for Phase 3 Initiating Coverage of Cadrenal Therapeutics Inc
We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...
408 Views
Cadrenal Therapeutics Inc - September 16, 2024
We are initiating coverage of Cadrenal Therapeutics, Inc. (CVKD) with a valuation of $30.00. Cadrenal is a clinical stage biopharmaceutical...
391 Views